Pınar ŞEN GÖKÇEİMAM, Esra AYDIN SÜNBÜL, Tuba GÜÇTEKİN, Murat SÜNBÜL

Hipertansiyon Hastalarında Bilinçli Farkındalık Düzeyinin İlaç Uyumuna Etkisi

ÖZ Amaç: Çalışmada hipertansiyon hastalarının bilinçli farkındalık düzeylerinin antihipertansif ilaç uyumuna olan etkisi araştırılmıştır. Gereç ve Yöntem: Çalışmaya katılmaya onam veren kişilerden okur yazar olan, en az bir yıldır antihipertansif kullanıyor olan 18-65 yaş aralığındaki hipertansif hastalar çalışmaya dahil edilmiştir. Ölçek doldurmayı engelleyecek düzeyde mental yetersizliği ve/veya mental hastalığı bulunanlar çalışma dışında bırakılmıştır. Kesitsel ve tanımlayıcı bir araştırmadır. Katılımcılara sosyo-demografik veri formu, Bilinçli Farkındalık ölçeği (BFÖ) ve Modifiye Morisky Tedavi Uyum ölçeği uygulanmıştır. Bulgular: Yaş ortalaması düşük olan hastaların ilaç uyumu düşük olarak saptandı. Cinsiyet, eğitim düzeyi, çalışma durumu ve medeni durum açısından bakıldığında gruplar arasında ilaç uyumu açısından anlamlı fark yoktu. Ailesinde hipertansiyon öyküsü olanlarda ilaç uyumunun düşük olma oranı orta-yüksek olma oranına kıyasla anlamlı şekilde yüksekti. İlaç uyumu skorlarında hipertansiyon hastalığının süresi açısından istatistiksel açıdan anlamlı bir fark yoktu. BFÖ skor ortalamaları ilaç uyumu orta-yüksek olanlarda anlamlı şekilde daha yüksekti. Sonuç: Çalışma sonuçlarımız hipertansif hasta grubunda ilaç uyumunun düşük olduğu, farkındalık ve uyum arasında anlamlı bir ilişki olduğu yönünde kanıt sunmaktadır. Diğer kronik hastalıklarda olduğu gibi hipertansiyon hastalarında da ilaç uyumunun artırılması, bu amaçla ilaç uyumunu etkileyen farkındalık düzeyinin artırılması hayati önem arz etmektedir. Çalışma verilerimiz bu alanda yapılacak klinik müdahaleler için farkındalık oluşturacaktır.

The Effect of Mindfulness Level on Drug Adherence in Hypertension Patients

Aim: The effect of mindfulness levels of hypertensive patients on drug adherence was studied. Materials and Methods: Hypertensive patients between the ages of 18 and 65 years, who gave their consent to participate in the study, were literate and had been using antihypertensive drugs for at least one year, were included in the study. Those who had mental retardation and/or mental disease that prevented filling the scale were excluded from the study. It is a cross-sectional and descriptive study. Socio-demographic data form and the Mindful Attention Awareness scale (MAAS) and Modified Morisky Adherence scale were applied to the participants. Results: Drug adherence of the patients with a low mean age was found to be low. There was no significant difference between the groups in terms of drug compliance when it was examined in terms of gender, education level, employment status and marital status. In those with a family history of hypertension, the rate of low drug adherence was significantly higher compared to the rate of medium-high drug adherence, there was no statistically significant difference in drug adherence scores in terms of hypertension duration of disease. The mean MAAS scores were significantly higher in those with medium- high drug adherence. Conclusion: Our study results provide evidence that drug adherence was low in the hypertensive patient group and there was a significant relationship between mindfulness and adherence. As in other chronic diseases, it is vital to increase drug adherence in hypertensive patients and to increase the level of mindfulness affecting drug adherence for this purpose. Our study data will raise awareness for clinical interventions in this area.

PDF

___

KAYNAKLAR 1. Chow CK, Teo KK, Rangarajan S, Islam S, Gupta R, Avezum A, et al. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA. 2013;310:959-68.
2. Burnier M, Egan BM. Adherence in Hypertension. Circ Res. 2019;124:1124- 40.
3. Lauffenburger JC, Landon JE, Fischer MA. Effect of Combination Therapy on Adherence Among US Patients Initiating Therapy for Hypertension: a Cohort Study. J Gen Intern Med. 2017;32:619-25.
4. Hill MN, Miller NH, Degeest S; American Society of Hypertension Writing Group, Materson BJ, Black HR, Izzo JL Jr, et al. Adherence and persistence with taking medication to control high blood pressure. J Am Soc Hypertens. 2011;5:56-63.
5. Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31:1281-357.
6. Hughes JW, Fresco DM, Myerscough R, van Dulmen MH, Carlson LE, Josephson R. Randomized controlled trial of mindfulness-based stress reduction for prehypertension. Psychosom Med. 2013;75:721-8. 7. Goldstein CM, Josephson R, Xie S, Hughes JW. Current perspectives on the use of meditation to reduce blood pressure. Int J Hypertens. 2012;2012:578397.
8. Brown KW, Ryan RM. The benefits of being present: mindfulness and its role in psychological well-being. J Pers Soc Psychol. 2003;84:822-48.
9. Ozyesil Z, Arslan C, Kesici Ş, Deniz ME. Adaptation of the Mindful Attention Awareness Scale into Turkish. Education and Science. 2011;36:224-35.
10. Simpson SH, Johnson JA, Farris KB, Tsuyuki RT. Development and validation of a survey to assess barriers to drug use in patients with chronic heart failure. Pharmacotherapy. 2002;22:1163-72.
11. Vural B, Teberru Acar Ö, Topsever P, Filiz TM. Reliability And Validity Of Turkish Version Of Modified Morisky Scale. The Journal of Turkısh Familiy Physician. 2012;3:17-20.
12. Nejati S, Zahiroddin A, Afrookhteh G, Rahmani S, Hoveida S. Effect of Group Mindfulness-Based Stress-Reduction Program and Conscious Yoga on Lifestyle, Coping Strategies, and Systolic and Diastolic Blood Pressures in Patients with Hypertension. J Tehran Heart Cent. 2015;10:140-8.
13. Abegaz TM, Shehab A, Gebreyohannes EA, Bhagavathula AS, Elnour AA. Nonadherence to antihypertensive drugs: A systematic review and meta- analysis. Medicine (Baltimore). 2017;96:e5641.
14. Yassine M, Al-Hajje A, Awada S, Rachidi S, Zein S, Bawab W, et al. Evaluation of medication adherence in Lebanese hypertensive patients. J Epidemiol Glob Health. 2016;6:157-67.
15. Gniwa Omezzine R, Akkara A, Abdelkafi Koubaa A, Belguith Sriha A, Rdissi A, Amamou K. Predictors of Poor Adherence to Hypertension Treatment. Tunis Med. 2019;97:564-71.
16. Brown MT, Bussell JK. Medication adherence: WHO cares? Mayo Clin Proc. 2011;86:304-14.
17. Gavrilova A, Bandere D, Rutkovska I, Šmits D, Mauriņa B, Poplavska E, et al. Knowledge about Disease, Medication Therapy, and Related Medication Adherence Levels among Patients with Hypertension. Medicina (Kaunas). 2019;55:715.
18. Essomba NE, Hamadou B, Kedy Koum DC, Atemkeng A, Coppieters Y. Facteurs de Non Observance au Traitement Antihypertenseur chez les Adultes à Douala. Health Sci Dis. 2017;18:51-7.
19. Strauch B, Petrák O, Zelinka T, Rosa J, Somlóová Z, Indra T, et al. Precise assessment of noncompliance with the antihypertensive therapy in patients with resistant hypertension using toxicological serum analysis. J Hypertens. 2013;31:2455-61.
20. Irvin MR, Shimbo D, Mann DM, Reynolds K, Krousel-Wood M, Limdi NA, et al. Prevalence and correlates of low medication adherence in apparent treatment-resistant hypertension. J Clin Hypertens (Greenwich). 2012;14:694-700.
21. Dias A, Pereira C, Monteiro MJ, Santos C. Patients’ beliefs about medicines and adherence to medication in ischemic heart disease. Aten Primaria. 2014;46(Suppl 5):101-6.
22. Krousel-Wood MA, Muntner P, Islam T, Morisky DE, Webber LS. Barriers to and determinants of medication adherence in hypertension management: perspective of the cohort study of medication adherence among older adults. Med Clin North Am. 2009;93:753-69.
23. Qvarnström M, Kahan T, Kieler H, Brandt L, Hasselström J, Bengtsson Boström K, et al. Persistence to antihypertensive drug treatment in Swedish primary healthcare. Eur J Clin Pharmacol. 2013;69:1955-64.
24. Ambaw AD, Alemie GA, W/Yohannes SM, Mengesha ZB. Adherence to antihypertensive treatment and associated factors among patients on follow up at University of Gondar Hospital, Northwest Ethiopia. BMC Public Health. 2012;12:282.
25. Shi L, Zhang D, Wang L, Zhuang J, Cook R, Chen L. Meditation and blood pressure: a meta-analysis of randomized clinical trials. J Hypertens. 2017;35:696-706.
26. Al-Ramahi R. Adherence to medications and associated factors: A cross- sectional study among Palestinian hypertensive patients. J Epidemiol Glob Health. 2015;5:125-32.
27. Petit G, Berra E, Georges CMG, Capron A, Huang QF, Lopez-Sublet M, et al. Impact of psychological profile on drug adherence and drug resistance in patients with apparently treatment-resistant hypertension. Blood Press. 2018;27:358-67.
28. Foster G, Taylor SJ, Eldridge SE, Ramsay J, Griffiths CJ. Self-management education programmes by lay leaders for people with chronic conditions. Cochrane Database Syst Rev. 2007;(4):CD005108.
29. Schrieber L, Colley M. Patient education. Best Pract Res Clin Rheumatol. 2004;18:465-76.
30. McManus RJ, Mant J, Haque MS, Bray EP, Bryan S, Greenfield SM, et al. Effect of self-monitoring and medication self-titration on systolic blood pressure in hypertensive patients at high risk of cardiovascular disease: the TASMIN-SR randomized clinical trial. JAMA. 2014;312:799-808.
31. Loucks EB, Gilman SE, Britton WB, Gutman R, Eaton CB, Buka SL. Associations of Mindfulness with Glucose Regulation and Diabetes. Am J Health Behav. 2016;40:258-67.
32. Zernicke KA, Campbell TS, Speca M, McCabe-Ruff K, Flowers S, Carlson LE. A randomized wait-list controlled trial of feasibility and efficacy of an online mindfulness-based cancer recovery program: the eTherapy for cancer applying mindfulness trial. Psychosom Med. 2014;76:257-67.
33. Pradhan EK, Baumgarten M, Langenberg P, Handwerger B, Gilpin AK, Magyari T, et al. Effect of Mindfulness-Based Stress Reduction in rheumatoid arthritis patients. Arthritis Rheum. 2007;57:1134-42.
34. Griffiths K, Camic PM, Hutton JM. Participant experiences of a mindfulness- based cognitive therapy group for cardiac rehabilitation. J Health Psychol. 2009;14:675-81.
35. Medina WL, Wilson D, de Salvo V, Vannucchi B, de Souza ÉL, Lucena L, et al. Effects of Mindfulness on Diabetes Mellitus: Rationale and Overview. Curr Diabetes Rev. 2017;13:141-7.